ENDV - Endonovo Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0122
+0.0010 (+8.93%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.0112
Open0.0115
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0114 - 0.0127
52 Week Range0.0110 - 0.0661
Volume1,432,350
Avg. Volume2,165,161
Market Cap6.377M
Beta (3Y Monthly)2.85
PE Ratio (TTM)N/A
EPS (TTM)-0.0180
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire27 days ago

    Endonovo Therapeutics Announces Partnership with Second Hospital

    LOS ANGELES, CA , March 29, 2019 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced an agreement with a nationally recognized hospital.

  • GlobeNewswirelast month

    Endonovo Therapeutics Granted Trademarks for WoundPulse and OrthoHalo

    LOS ANGELES, CA, March 22, 2019 -- March 22, 2019 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive.

  • GlobeNewswirelast month

    Endonovo Therapeutics Partners with SunMED Medical Systems

    LOS ANGELES, CA, March 20, 2019 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), Alan Collier, Endonovo’s Chief Executive Officer, stated "We are.

  • GlobeNewswire2 months ago

    Endonovo Therapeutics Files Lawsuit against KVP International Inc., Orthocor Medical Inc., and Careus Corp. for Patent Infringement

    Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, filed a patent infringement lawsuit today in the U.S. District Court for the Central District of California against KVP INTERNATIONAL, INC., a California Corporation, ORTHOCOR MEDICAL, INC., a Delaware Corporation, and CAERUS CORP., a Minnesota Corporation. KVP has even trademarked the KVP Cura name it uses to refer to its infringing products and/or product line The KVP Cura line infringes, where according to KVP’s own website, “the KVP Cura line reduces pain and increases blood flow, providing effective therapy for a variety of ailments.

  • GlobeNewswire3 months ago

    Endonovo Therapeutics Issues Shareholder Letter and Update

    It is with great pleasure that I provide you with an update on Endonovo’s business development initiatives and our recent accomplishments. From a financing perspective, we recently entered into a line of credit at a 6% discount to market to reduce dilution for interim financing.

  • GlobeNewswire4 months ago

    Endonovo Therapeutics Enters into $10 million Common Stock Purchase Agreement with Azure Capital

    Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, announced today it has executed a Common Stock Purchase Agreement (the “Purchase Agreement”) with Azure Capital (“Azure”) to sell up to $10 Million in common stock to Azure over a term of 36 months, commencing after a registration statement related to the transaction has been filed and declared effective by the U.S. Securities and Exchange Commission. Alan Collier, CEO of Endonovo Therapeutics, stated, “We are excited about this partnership with Azure Capital and the opportunity of potential future access to capital at attractive terms.

  • GlobeNewswire4 months ago

    Endonovo Therapeutics Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office

    LOS ANGELES, CA, Dec. 18, 2018 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™.

  • GlobeNewswire4 months ago

    Endonovo Expands SofPulse Commercialization

    LOS ANGELES, CA, Dec. 13, 2018 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™.

  • GlobeNewswire5 months ago

    Endonovo Therapeutics Announces Strategic Relationship with US Authentic Trading Company

    LOS ANGELES, CA, Dec. 03, 2018 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™.

  • GlobeNewswire6 months ago

    Endonovo Therapeutics Announces Complimentary New Product

    LOS ANGELES, CA, Nov. 08, 2018 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™.